GENENTECH/IDEC RITUXAN NON-HODGKIN'S LYMPHOMA THERAPY HAS DIRECT PRICE OF $8,904; FIRST MONOCLONAL ANTIBODY FOR CANCER ALSO IS IDEC's FIRST PRODUCT